09 - 19

Citryll collaborates with leading NET researcher Dr. Markus Hoffmann

Oss, The Netherlands, Erlangen, Germany September 18, 2019 —https://citryll.com/ announced today that it has
established a collaboration with Dr. Markus Hoffmann of the Department of Medicine 3, Friedrich Alexander University
of Erlangen-Nürnberg to investigate the mechanism of action (MoA) of its lead CIT-013 (tACPA) antibody programme.
CIT-013 interferes with the formation, function and clearance of neutrophil extracellular traps (NETs), downstream of the
peptidylarginine deiminase (PAD) dependant citrullination pathway

Dr. Hoffmann and colleagues investigate the impact that cells undergoing NET formation have on the development and
maintenance of inflammatory diseases such as arthritis, Systemic Lupus Erythematosus (SLE), and gout. The
regulatory role of NETs has been an important focus of their research interest with ample publications on the subject.

“Neutrophils in general, and NETs in particular, are increasingly recognized as an important player in an ever-growing list of pathological conditions. As inhibitors of the pro-inflammatory effects of NETs, tACPA are very interesting new candidates for the treatment of chronic inflammatory diseases.”, says Dr. Hoffmann.

“CIT-013 inhibits formation of NETs, which prevents the release of new autoantigens and proinflammatory factors in tissues and circulation. I am confident that our collaboration with Dr. Hoffmann will help to further understand CIT-013’s MoA.”, says CSO Renato Chirivi.

“We believe that drugs that target NET biology have the potential to create breakthrough treatments to prevent or treat human disease such as lupus, vasculitis, and organ damage due to sepsis. Citryll’s approach does not broadly target inflammation or acquired immunity, instead it extinguishes the source of autoantigens and NET-derived toxic molecules in the safest way currently possible”, says CEO Helmuth van Es.

About Citryll

Citryll BV is a private pharmaceutical company based in Oss, the Netherlands that is dedicated to the development and commercialization of therapeutics that target NETosis and NETs. Citryll was founded by ModiQuest B.V., originator of the tACPA patents, Helmuth van Es, CEO Citryll (co-founder of Audion Therapeutics, Galapagos, Antabio and Effecta Pharma), and Renato Chirivi, CSO Citryll and co-inventor of tACPA antibodies.

About the Immunology and Rheumatology Department (Medicine 3) of the Friedrich Alexander University

(https://www.uk-erlangen.de) The department is a clinical and translational research centre dedicated to understand the pathogenesis of inflammatory and autoimmune diseases. It combines an Experimental Medicine Centre based on a 21-bed ward for innovative treatment of patients with severe inflammatory disease and an outpatient clinic for inflammatory and autoimmune diseases, and a Translational Research Centre, dedicated to elucidate the pathogenesis of inflammatory disease. The TRC follows a comprehensive research approach based on the analysis of patient material as well as tailored disease modelling by high-level cell- and molecular biology. Scientific competence of the centre is underlined by its labelling as ”European Centre of Excellence” awarded by the European League Against Rheumatism (EULAR) for high-level disease-oriented research. The particular strength of this centre is based on a tight interaction between patient-orientated research and translational science realized by joint project groups consisting of biologists and medical doctors, thus allowing translation and reverse translation of data between disease models and human disease.

Share on social media:

Other news

06-26

Exploring the Emerging Role of Extracellular Traps in Immune-Mediated Inflammatory Diseases

Earlier this week, Citryll hosted an educational webinar bringing together leading scientific and clinical experts to discuss the evolving understanding

04-26

Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013

Expected to provide exclusivity into 2039 Oss, Netherlands – 15 April 2026 – Citryll, a biotech company pioneering a transformative

02-26

First patient dosed in Citryll’s imaging study evaluating distribution and target engagement of CIT-013

PET-based imaging study designed to assess the biodistribution of CIT-013 and associate disease activity with CIT-013 target disposition in participants

02-26

Employee Spotlight – Catarina Antunes

As a key part of Citryll’s team, Catarina Antunes, Program & Communications Manager, plays a central role in driving cross‑functional

12-25

End of Year Newsletter 2025

As I look back on 2025, it has been a truly remarkable year for the Citryll team. With a laser

12-25

First Patient Dosed In Citryll’s Phase IIA Hidradenitis Suppurativa Trial

Multi-center, randomized study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with hidradenitis suppurativa Marks the